JANSSEN Alzheimer Immunotherapy Research & Development

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, JANSSEN Alzheimer Immunotherapy Research & Development sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

JANSSEN Alzheimer Immunotherapy Research & Development: 8 sponsored US clinical trials, none currently recruiting.

JANSSEN Alzheimer Immunotherapy Research & Development sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimers Disease, with 1 trials.

Upper-quartile sponsor footprint

JANSSEN Alzheimer Immunotherapy Research & Development sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 2

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

NCT01284387
COMPLETED Phase 2

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773
TERMINATED Phase 3

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT00937352
COMPLETED Phase 3

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055
COMPLETED Phase 3

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

NCT00574132
TERMINATED Phase 2

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

NCT00606476
COMPLETED Phase 2

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
TERMINATED Phase 2

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 3

Therapeutic Areas

Alzheimers Disease 1

How the JANSSEN Alzheimer Immunotherapy Research & Development early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 3 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Alzheimers Disease (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

JANSSEN Alzheimer Immunotherapy Research & Development: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

JANSSEN Alzheimer Immunotherapy Research & Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share JANSSEN Alzheimer Immunotherapy Research & DevelopmentAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
JANSSEN Alzheimer Immunotherapy Research & Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

JANSSEN Alzheimer Immunotherapy Research & Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this JANSSEN Alzheimer Immunotherapy Research & Development page

8 registered trials is a research-attention snapshot, not an endorsement of JANSSEN Alzheimer Immunotherapy Research & Development or any single study.

  • None of JANSSEN Alzheimer Immunotherapy Research & Development's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Alzheimers Disease is the condition JANSSEN Alzheimer Immunotherapy Research & Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimers Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. JANSSEN Alzheimer Immunotherapy Research & Development pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.